here are strong interactions between cardiovascular and renal diseases. "Cardiorenal syndrome" indicates the presence or development of renal dysfunction in patients with heart failure (HF). 1,2 Although medical therapy, including angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), -blockers, and spironolactone, for HF has advanced significantly during the past decade, the prognosis and quality of life of patients with HF remains poor. 3-6 Furthermore, it is noteworthy that impaired renal function is associated with poor outcomes among HF patients. 1,2 Thus, therapy addressing the issue of renal protection is important for patients with HF.
tional class, body weight, blood pressure, surface ECG, and B-type natriuretic peptide (BNP) levels. The QRS duration was measured in the lead with the longest QRS duration as the interval between the onset of the QRS complex and the terminal isoelectric component of the complex. In patients with AF, the QRS duration was averaged over 5 beats. Echocardiographic measurements and renal function test were performed before and 3 months after CRT/CRTD. Crosssectional image-guided M-mode echocardiography of the left ventricle was recorded at the level of mitral valve leaflet. The LV end-diastolic diameter was measured at the onset of the QRS complex and the LV end-systolic diameter as the smallest diameter. The LVEF was calculated Simpson's method using the apical 4-chamber view. Patients received standard treatment with diuretics (furosemide with or without spironolactone), ACEI, and/or ARB, and -blockers to the optimal points.
Statistical Analyses
Data are expressed as mean ± standard error for continuous variables and as numbers (proportions) for categorical variables. Differences between the 2 groups were assessed using the t-test. The mortality was assessed by Kaplan-Meier survival analysis. The predictors for the deterioration of renal function were assessed by multivariate logistic regression analysis. A p-value <0.05 was considered statistically significant. All statistical analyses were performed using SPSS (SPSS Inc, Chicago, IL, USA) for Windows Version 13 (Microsoft Corp, Redmond, WA, USA).
Results

Baseline Patients' Characteristics
The baseline clinical characteristics of the 23 patients are summarized in Table 1 
Responders and Non-Responders to CRT
Responders were defined as patients who showed an improved EF (ΔEF) >0% by echocardiography 3 months after CRT. At the 3-month follow-up, 13 (56.5%) patients were classified as responders and the 10 (43.5%) non-responders had a ΔEF ≤0%. In all patients, biventricular pacing was confirmed for more than 95% of daily heart beats in the 2 groups during follow up. The ΔEF measured by echocardiography in the responders was +8.7±2.7%, and that of nonresponders was -6.9±1.3%. Baseline characteristics including NYHA functional class, blood pressure, QRS duration, EF by echocardiography, plasma concentrations of BNP, eGFR, prescription of ACEI and/or ARB, -blockers, and dose of diuretics did not differ between the 2 groups before CRT implantation ( Table 2 ).
In the responders, the improvement in EF was accompanied by a reduction in the plasma concentration of BNP (from 643.1±177.5 to 370.8±116.4, p<0.01) and a rise in systolic blood pressure (from 93.7±4.2 to 98.4±2.9, p<0.05), as well as a shortening of QRS duration (from 176.1±11.3 to 145.8±7.3, p<0.05). There was no significant difference in NYHA functional class after CRT/CRTD between the responders and the non-responders. The non-responders failed to show improvement in any of the study parameters. Furthermore, there was a significant difference in the survival rates of responders and non-responders (p<0.05) (Fig 1) .
Effects of CRT on Renal Function
There was a significant difference in the ΔeGFR of responders and non-responders (+3.0±3.4 vs -11.5±4.3 ml· min -1 ·1.73m -2 ; p<0.05) (Table2, Fig2). Furthermore, even in patients with renal dysfunction defined as eGFR <60ml/min before CRT implantation, there was a significant difference between the responders (n=8) and non-responders (n=7) in ΔeGFR (+5.8±5.0 vs -16.0±4.6; p<0.01) ( Table 3) . Table 4 shows the predictors of deterioration in renal function defined as ΔeGFR <0. The CRT response was an independent predictor for preserving renal function (odds ratio 0.111 [0.016-0.778], p=0.027).
Effects of CRT on Medication
Of the 13 responders, 11 (85%) were prescribed ACEI/ARB before CRT, and that increased to 13 patients (100%) after CRT. In contrast, in the non-responders, the prescription rate of ACEI/ARB before CRT was 70%, and it declined to 60% after CRT, resulting in a significant difference between the responders and the non-responders in the ACEI/ARB prescription rate after CRT (p<0.05). Although there was no difference in the ratio of prescriptions ofblockers 3 months after CRT implantation, up-titration ofblockers was achieved more often in the CRT responders than the non-responders (p<0.05). These favorable effects were preserved even in patients with renal dysfunction before CRT implantation (Table 3) . Diuretics were used evenly in the 2 groups before and after CRT implantation.
Discussion
The importance of this study is that it reveals that in responders to CRT renal function is preserved, even in patients with renal insufficiency. In addition, the responders to CRT can maintain ARB/ACEI therapy and significantly increase the titration of -blockers compared with non-responders.
There are strong interactions between cardiovascular and renal disease. Decreased GFR has consistently been found to be an independent risk factor for cardiovascular disease outcomes and all-cause mortality in patients with HF. 10, 11 We have recently revealed that, despite optimal medical therapy, the clinical course of renal function in patients with IDCM is less likely to be good; renal insufficiency occurs in 20% during the first 8 years of follow-up and in 50% at the 20-year follow-up, even if renal function was preserved at the initial diagnosis. 12 Furthermore, some patients with the most severe disease may not tolerate taking medications because of factors such as hypotension, hyperkalemia, renal dysfunction itself, and other adverse effects, resulting in a rapid decline in renal function and an increase in early mortality. 12, 13 Thus, new treatment strategies are needed for HF patients, especially those with renal insufficiency.
CRT has recently been introduced as a new option for HF patients. Many clinical trials have shown that it can improve cardiac function and symptoms, reduce hospitalization, and prolong life in appropriately selected patients. [14] [15] [16] [17] [18] [19] [20] Although there has been 1 report of the relationship between CRT and renal function, 21 the effects of CRT on renal function in patients with renal insufficiency remain unknown. Because the risk of cardiovascular events becomes evident at an estimated GFR <60 ml/min, in the present study we defined eGFR <60 ml/min as renal insufficiency. [22] [23] [24] [25] Some mechanisms of the beneficial effects of CRT have been reported. Resynchronization leads to a sustained increase in LV performance and a diminution of mitral regurgitation and, in turn, a rise in perfusion pressure, a fall in cardiac filling pressure, and favorable LV remodeling. 8 These changes result in an increase in cardiac output 26 and an improvement of the autonomic imbalance. 27 The mechanisms of HF-induced/associated impaired renal function are diverse and not well-defined. 2 Hemodynamic abnormalities such as hypotension or low cardiac output, as well as neurohormonal factors, are thought to play an important role in the progression of renal dysfunction. 2, 12 In the present study, systolic blood pressure increased significantly in the CRT responder group. Ljungman et al have demonstrated that renal blood flow can be preserved if the cardiac index remains above 1.5 L · min -1 · mm -1 . 28 The mean cardiac index before CRT implantation in this study was 2.4± 0.2 L·min -1 ·mm -1 , and no patients showed a cardiac index below 1.5 L·min -1 ·mm -1 before CRT implantation, indicating that renal blood flow may have been preserved. However, these data do not allow us to exclude the possibility that the beneficial effect of CRT on renal function is secondary to hemodynamic improvement. Although we analyzed the correlation between ΔEF and ΔeGFR, there was no significant relationship between them. How can we explain these results? First, renal function represented by ΔeGFR seemed to be preserved rather than improved in the CRT responder group. Once renal function deteriorates to some extent, it might be difficult to achieve recovery, so it seems to be important to preserve renal function in these patients. Second, activation of systemic neurohormonal factors by CHF may be suppressed by CRT, resulting in inhibition of the renal rennin -angiotensin system, reactive oxygen species, inflammation, and the sympathetic nervous system, which are thought to be key factors in the progression of cardiorenal syndrome. 1 We have no data regarding these points, and further study must be carried out to reveal the related mechanisms.
Discontinuation of some medical therapy, such as ACEI and -blockers, can identify patients in whom renal function is likely to worsen. 12, 13 Diuretic usage in HF patients remains controversial and there are concerns that chronic use can cause adverse vascular effects, unfavorable neurohormonal activation, electrolyte imbalance, and life-threatening arrhythmias. 29 Thus, continuation of beneficial medical therapy and the dose of diuretics are important issues in the treatment of HF patients, especially those with cardiorenal syndrome. In the present study, the prescription rate of ACEI/ARB was higher in the CRT responders than in the non-responders, and up-titration of -blockers was significant in the CRT responder group compared with the non-responders. Importantly, these effects were preserved even in patients with renal insufficiency. The reasons for the nonprescription of ACEI/ARB and non-up-titration of -blockers were hypotension and hypotension-related symptoms in most patients. In the CRT responder group, systolic blood pressure increased significantly, and even prescription of ACEI/ARB and the titration of -blockers increased. The beneficial effects of CRT on hemodynamics result in increased tolerance of ACEI/ARB and -blockers, which in turn cuts the malignant cycle of HF. Therefore, both the direct effect of CRT on hemodynamic and neurohormonal factors, and the indirect effect, through increased medical therapy, might favorably work in concert in patients with cardiorenal syndrome. In contrast, there was no significant difference regarding the use and dose of diuretics between before and after CRT implantation in the present study. However, CRT may dramatically decrease the dose of diuretics in some patients. Whether CRT reduces the required doses of diuretics must be addressed by long-term and large-scale studies.
Study Limitations
First, this was not a randomized, prospective study. Second, the number of subjects was small, and may have affected the statistical analysis. However, the present study implies new benefits of CRT, especially in patients with cardiorenal syndrome, which will be of great importance in the clinical field.
Conclusions
Our study shows that CRT therapy has beneficial effects on renal function and maintenance of medical therapy for HF patients, even in patients with renal insufficiency. These results suggest the beneficial effects of CRT in patients with HF, and CRT therapy has great possibilities as a therapeutic option for patients with cardiorenal syndrome.
